IkT-001Pro

DRUG3 trials

Sponsors

Inhibikase Therapeutics Inc., Inhibikase Therapeutics

Conditions

CMLPulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Phase 1

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

CompletedNCT05623774

Inhibikase TherapeuticsCML

Start: 2022-12-16End: 2024-12-30Updated: 2025-11-06

Phase 2

A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

WithdrawnNCT06643143

Inhibikase TherapeuticsPulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Start: 2025-06-30End: 2027-06-30Updated: 2025-06-13

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

Not yet recruitingCTIS2024-520218-23-00

Inhibikase Therapeutics Inc.Pulmonary Arterial Hypertension

Target: 26Updated: 2026-04-29